Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma
Copyright © 2024 Elsevier Inc. All rights reserved..
BACKGROUND: Patients with multiple myeloma (MM) may be on therapy for years, which can lead to financial toxicity (FinTox) or time toxicity (TimeTox). The prevalence, predictors, and quality of life (QOL) impacts of FinTox and TimeTox during different phases of MM treatment have not been characterized.
PATIENTS AND METHODS: We conducted a single-center cross-sectional survey of patients with MM who had undergone transplantation. FinTox+ was defined as a COST-FACIT score <23, TimeTox+ as MM-related interactions (including phone calls) ≥1x weekly or ≥1x monthly in-person among far-residing patients, QOL using PROMIS Global Health, and functional status using patient-reported Karnofsky performance status (KPS).
RESULTS: Of 252 patients, 22% and 40% met FinTox+ and TimeTox+ criteria respectively. Respective FinTox+ and TimeTox+ proportions were 22%/37% for patients on maintenance, 22%/82% with active therapy, and 20%/14% with observation. FinTox+ predictors included annual income (P < .01) and out-of-pocket costs (P < .01). TimeTox+ predictors included disease status (P < .001), caregiver status (P = .01), far-residing status (P < .001), and out-of-pocket costs (P = .03). FinTox+ was associated with a clinically meaningful decrease in mental QOL, while TimeTox+ patients were more likely to have KPS ≤ 80.
CONCLUSIONS: In our large study, monetary status but not disease status predicted FinTox. Over a third of patients on maintenance reported TimeTox. FinTox+ was associated with decreased mental health, while TimeTox+ was associated with worse performance status. These two toxicities may negatively impact patient wellbeing, and studies of strategies to mitigate their impact are in development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical lymphoma, myeloma & leukemia - (2024) vom: 23. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Banerjee, Rahul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Financial toxicity |
|---|
| Anmerkungen: |
Date Revised 23.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.clml.2024.02.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370112032 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370112032 | ||
| 003 | DE-627 | ||
| 005 | 20240324235523.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2024.02.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1345.xml |
| 035 | |a (DE-627)NLM370112032 | ||
| 035 | |a (NLM)38521640 | ||
| 035 | |a (PII)S2152-2650(24)00090-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Banerjee, Rahul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Patients with multiple myeloma (MM) may be on therapy for years, which can lead to financial toxicity (FinTox) or time toxicity (TimeTox). The prevalence, predictors, and quality of life (QOL) impacts of FinTox and TimeTox during different phases of MM treatment have not been characterized | ||
| 520 | |a PATIENTS AND METHODS: We conducted a single-center cross-sectional survey of patients with MM who had undergone transplantation. FinTox+ was defined as a COST-FACIT score <23, TimeTox+ as MM-related interactions (including phone calls) ≥1x weekly or ≥1x monthly in-person among far-residing patients, QOL using PROMIS Global Health, and functional status using patient-reported Karnofsky performance status (KPS) | ||
| 520 | |a RESULTS: Of 252 patients, 22% and 40% met FinTox+ and TimeTox+ criteria respectively. Respective FinTox+ and TimeTox+ proportions were 22%/37% for patients on maintenance, 22%/82% with active therapy, and 20%/14% with observation. FinTox+ predictors included annual income (P < .01) and out-of-pocket costs (P < .01). TimeTox+ predictors included disease status (P < .001), caregiver status (P = .01), far-residing status (P < .001), and out-of-pocket costs (P = .03). FinTox+ was associated with a clinically meaningful decrease in mental QOL, while TimeTox+ patients were more likely to have KPS ≤ 80 | ||
| 520 | |a CONCLUSIONS: In our large study, monetary status but not disease status predicted FinTox. Over a third of patients on maintenance reported TimeTox. FinTox+ was associated with decreased mental health, while TimeTox+ was associated with worse performance status. These two toxicities may negatively impact patient wellbeing, and studies of strategies to mitigate their impact are in development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Financial toxicity | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Quality of life | |
| 650 | 4 | |a Supportive care | |
| 650 | 4 | |a Time toxicity | |
| 700 | 1 | |a Cowan, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega, Marivel |e verfasserin |4 aut | |
| 700 | 1 | |a Missimer, Constance |e verfasserin |4 aut | |
| 700 | 1 | |a Carpenter, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Oshima, Masumi Ueda |e verfasserin |4 aut | |
| 700 | 1 | |a Salit, Rachel B |e verfasserin |4 aut | |
| 700 | 1 | |a Vo, Phuong T |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Catherine J |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Rohtesh S |e verfasserin |4 aut | |
| 700 | 1 | |a Kuderer, Nicole M |e verfasserin |4 aut | |
| 700 | 1 | |a Shankaran, Veena |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Stephanie J |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Christopher T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d 2010 |g (2024) vom: 23. Feb. |w (DE-627)NLM195738748 |x 2152-2669 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clml.2024.02.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 02 | ||